FR180204, > = 98 %(HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

FR180204 has been used as ERK inhibitor:to block extracellular-signal-regulated kinase (ERK) in order to validate whether homeobox B7 (HOXB7) regulates the migration and proliferation process via AKT/mitogen-activated protein kinases (MAPK) signalingof extracellular-signal-regulated kinase (ERK) to study the effects of signaling pathway inhibitors on differentiation and cell traction stress to determine if phosphorylation of this signaling protein is essential for mesenchymal stromal cell (MSC) derived therapeutic efficacy

Biochem/physiol Actions

FR180204 is a potent, cell-permeable, ATP-competitive inhibitor of ERK1 and ERK2 (mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2).

It can be used to study the roles of ERK as well as for drug development.

Features and Benefits

This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle